Trials / Active Not Recruiting
Active Not RecruitingNCT06487858
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
A Multicenter Open-Label Phase 1a/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- BeOne Medicines · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human (FIH) study that will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-R046 as a single agent and in combination with tislelizumab (BGB-A317) in participants with advanced or metastatic immune-sensitive solid tumors.
Detailed description
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-R046 | Intravenous administration |
| DRUG | Tislelizumab | Intravenous administration |
Timeline
- Start date
- 2024-07-16
- Primary completion
- 2027-12-01
- Completion
- 2027-12-01
- First posted
- 2024-07-05
- Last updated
- 2026-03-18
Locations
8 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06487858. Inclusion in this directory is not an endorsement.